Drug Trial Radar · NCT02003209
Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer
Last checked: Nov 19, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
315
Actual
Start
Feb 18, 2014
Primary completion
Oct 31, 2016
Study completion Jun 30, 2025
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- Collaborators
- NRG Oncology
- First posted
- Dec 6, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This randomized phase III trial studies docetaxel, carboplatin, trastuzumab, and pertuzumab with estrogen deprivation to see how they work compared to docetaxel, carboplatin, trastuzumab, and pertuzumab without estrogen deprivation in treating patients with hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-positive breast cancer that is operable or has spread from where it started to nearby tissue or lymph nodes (locally advanced). Drugs used in chemotherapy, such as docetaxel, carboplatin, trastuzumab, and pertuzumab, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Estrogen can cause the growth of breast cancer cells. Hormone therapy using goserelin acetate and aromatase inhibition therapy may fight breast cancer by blocking the use of estrogen by the tumor cells. Radiation therapy uses high energy x rays to kill tumor cells. Giving combination chemotherapy and radiation therapy with or without hormone therapy may be an effective treatment for hormone receptor-positive, HER2-positive, operable or locally advanced breast cancer.
Conditions
- HER2-Positive Breast Carcinoma
- Hormone Receptor-Positive Breast Carcinoma
- Stage IB Breast Cancer AJCC v7
- Stage IIA Breast Cancer AJCC v6 and v7
- Stage IIB Breast Cancer AJCC v6 and v7
- Stage IIIA Breast Cancer AJCC v7
- Stage IIIB Breast Cancer AJCC v7
- Stage IIIC Breast Cancer AJCC v7
Interventions
Aromatase Inhibition TherapyDrug
Given at the investigator's discretion
CarboplatinDrug
Given IV
Cytology Specimen Collection ProcedureOther
Undergo 2 core biopsies
DocetaxelDrug
Given IV
Goserelin AcetateDrug
Given SC
Laboratory Biomarker AnalysisOther
Correlative studies
PertuzumabBiological
Given IV
Quality-of-Life AssessmentOther
Ancillary studies
Therapeutic Conventional SurgeryProcedure
Undergo lumpectomy or mastectomy
TrastuzumabBiological
Given IV
Whole Breast IrradiationRadiation
Undergo whole breast irradiation
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent of Patients With Pathological Complete Response (pCR) in the Breast and Post Therapy Lymph NodesTime frame: Up to 2.8 years (when all patients completed primary breast surgery)
Locations
732 sites in 2 countries. Site status is shown where the registry gives one.
Fairbanks Memorial Hospital
Fairbanks, Alaska
CHI Saint Vincent Cancer Center Hot Springs
Hot Springs, Arkansas
Kaiser Permanente-Anaheim
Anaheim, California
Kaiser Permanente-Deer Valley Medical Center
Antioch, California
PCR Oncology
Arroyo Grande, California
Sutter Auburn Faith Hospital
Auburn, California
Sutter Cancer Centers Radiation Oncology Services-Auburn
Auburn, California
Kaiser Permanente-Baldwin Park
Baldwin Park, California
Kaiser Permanente-Bellflower
Bellflower, California
Alta Bates Summit Medical Center-Herrick Campus
Berkeley, California
Mills-Peninsula Medical Center
Burlingame, California
Sutter Cancer Centers Radiation Oncology Services-Cameron Park
Cameron Park, California
East Bay Radiation Oncology Center
Castro Valley, California
Eden Hospital Medical Center
Castro Valley, California
Sutter Davis Hospital
Davis, California
Epic Care-Dublin
Dublin, California
Bay Area Breast Surgeons Inc
Emeryville, California
Epic Care Partners in Cancer Care
Emeryville, California
Kaiser Permanente-Fontana
Fontana, California
Kaiser Permanente-Fremont
Fremont, California
Kaiser Permanente-Fresno
Fresno, California
Kaiser Permanente South Bay
Harbor City, California
Kaiser Permanente-Irvine
Irvine, California
Loma Linda University Medical Center
Loma Linda, California
Kaiser Permanente Los Angeles Medical Center
Los Angeles, California
Kaiser Permanente West Los Angeles
Los Angeles, California
Cedars Sinai Medical Center
Los Angeles, California
Contra Costa Regional Medical Center
Martinez, California
Memorial Medical Center
Modesto, California
Kaiser Permanente-Modesto
Modesto, California
El Camino Hospital
Mountain View, California
Palo Alto Medical Foundation-Camino Division
Mountain View, California
Palo Alto Medical Foundation-Gynecologic Oncology
Mountain View, California
Sutter Cancer Research Consortium
Novato, California
Wilma Chan Highland Hospital
Oakland, California
Alta Bates Summit Medical Center - Summit Campus
Oakland, California
Bay Area Tumor Institute
Oakland, California
Hematology and Oncology Associates-Oakland
Oakland, California
Kaiser Permanente-Oakland
Oakland, California
Saint Joseph Hospital - Orange
Orange, California
Showing 40 of 732 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.